As of June 14, 2025, Celsion Corp (CLSN) reports a ROE (Return on Equity) of -37.22%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Celsion Corp's ROE (Return on Equity)
Over recent years, Celsion Corp's ROE (Return on Equity) has shown a stable trend. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2021-12-31 | -37.22% |
| 2020-12-31 | -115.42% |
| 2019-12-31 | -115.73% |
| 2018-12-31 | -56.95% |
| 2017-12-31 | -76.40% |
This slight upward trend highlights how Celsion Corp manages its efficiency in generating profits from shareholders' equity over time.
Comparing Celsion Corp's ROE (Return on Equity) to Peers
To better understand Celsion Corp's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Celsion Corp (CLSN) | -37.22% |
| Oragenics Inc (OGEN) | 4987.46% |
| GT Biopharma Inc (GTBP) | 788.14% |
| ContraFect Corp (CFRX) | 549.79% |
| Abbvie Inc (ABBV) | 128.66% |
| Xynomic Pharmaceuticals Holdings Inc (XYNO) | 111.26% |
Compared to its competitors, Celsion Corp's ROE (Return on Equity) is about average compared to peers, reflecting standard industry returns on equity investment.